Knowledge  ||| S:0 E:10 ||| NN
about  ||| S:10 E:16 ||| IN
antipsychotic  ||| S:16 E:30 ||| JJ
long-acting  ||| S:30 E:42 ||| JJ
injections ||| S:42 E:52 ||| NNS
:  ||| S:52 E:54 ||| :
bridging  ||| S:54 E:63 ||| VBG
that  ||| S:63 E:68 ||| DT
gap  ||| S:68 E:72 ||| NN
Antipsychotics  ||| S:72 E:87 ||| NNS
in  ||| S:87 E:90 ||| IN
depot  ||| S:90 E:96 ||| NNS
( ||| S:96 E:97 ||| -LRB-
or  ||| S:97 E:100 ||| CC
; ||| S:100 E:101 ||| :
long-acting  ||| S:101 E:113 ||| JJ
injection ||| S:113 E:122 ||| NN
' ||| S:122 E:123 ||| POS
,  ||| S:123 E:125 ||| ,
LAI ||| S:125 E:128 ||| NNP
)  ||| S:128 E:130 ||| -RRB-
form  ||| S:130 E:135 ||| NN
are  ||| S:135 E:139 ||| VBP
shown  ||| S:139 E:145 ||| VBN
in  ||| S:145 E:148 ||| IN
this  ||| S:148 E:153 ||| DT
supplement  ||| S:153 E:164 ||| NN
to  ||| S:164 E:167 ||| TO
be  ||| S:167 E:170 ||| VB
a  ||| S:170 E:172 ||| DT
significant  ||| S:172 E:184 ||| JJ
component  ||| S:184 E:194 ||| NN
of  ||| S:194 E:197 ||| IN
clinical  ||| S:197 E:206 ||| JJ
practice ||| S:206 E:214 ||| NN
.  ||| S:214 E:216 ||| .
They  ||| S:216 E:221 ||| PRP
are  ||| S:221 E:225 ||| VBP
comparatively  ||| S:225 E:239 ||| RB
underresearched ||| S:239 E:254 ||| JJ
,  ||| S:254 E:256 ||| ,
which  ||| S:256 E:262 ||| WDT
may  ||| S:262 E:266 ||| MD
reflect  ||| S:266 E:274 ||| VB
their  ||| S:274 E:280 ||| PRP$
frequent  ||| S:280 E:289 ||| JJ
use  ||| S:289 E:293 ||| NN
witih  ||| S:293 E:299 ||| VBZ
poorly  ||| S:299 E:306 ||| RB
adherent  ||| S:306 E:315 ||| JJ
patients ||| S:315 E:323 ||| NNS
.  ||| S:323 E:325 ||| .
This  ||| S:325 E:330 ||| DT
supplement  ||| S:330 E:341 ||| NN
clearly  ||| S:341 E:349 ||| RB
demonstrates  ||| S:349 E:362 ||| VBZ
the  ||| S:362 E:366 ||| DT
need  ||| S:366 E:371 ||| NN
for  ||| S:371 E:375 ||| IN
that  ||| S:375 E:380 ||| DT
research ||| S:380 E:388 ||| NN
,  ||| S:388 E:390 ||| ,
highlighting  ||| S:390 E:403 ||| VBG
the  ||| S:403 E:407 ||| DT
variations  ||| S:407 E:418 ||| NNS
in  ||| S:418 E:421 ||| IN
dosing  ||| S:421 E:428 ||| NN
and  ||| S:428 E:432 ||| CC
the  ||| S:432 E:436 ||| DT
absence  ||| S:436 E:444 ||| NN
of  ||| S:444 E:447 ||| IN
established ||| S:447 E:458 ||| VBN
,  ||| S:458 E:460 ||| ,
specific  ||| S:460 E:469 ||| JJ
guidelines  ||| S:469 E:480 ||| NNS
in  ||| S:480 E:483 ||| IN
their  ||| S:483 E:489 ||| PRP$
use ||| S:489 E:492 ||| NN
.  ||| S:492 E:494 ||| .
Traditional  ||| S:494 E:506 ||| JJ
evidence-based  ||| S:506 E:521 ||| JJ
approaches  ||| S:521 E:532 ||| NNS
to  ||| S:532 E:535 ||| TO
systematic  ||| S:535 E:546 ||| JJ
reviews  ||| S:546 E:554 ||| NNS
are  ||| S:554 E:558 ||| VBP
of  ||| S:558 E:561 ||| IN
limited  ||| S:561 E:569 ||| JJ
utility  ||| S:569 E:577 ||| NN
in  ||| S:577 E:580 ||| IN
this  ||| S:580 E:585 ||| DT
area  ||| S:585 E:590 ||| NN
so  ||| S:590 E:593 ||| IN
this  ||| S:593 E:598 ||| DT
supplement ||| S:598 E:608 ||| NN
's  ||| S:608 E:611 ||| POS
blending  ||| S:611 E:620 ||| NN
of  ||| S:620 E:623 ||| IN
experimental  ||| S:623 E:636 ||| JJ
trials  ||| S:636 E:643 ||| NNS
with  ||| S:643 E:648 ||| IN
observational  ||| S:648 E:662 ||| JJ
research  ||| S:662 E:671 ||| NN
is  ||| S:671 E:674 ||| VBZ
particularly  ||| S:674 E:687 ||| RB
appropriate  ||| S:687 E:699 ||| JJ
and  ||| S:699 E:703 ||| CC
effective ||| S:703 E:712 ||| JJ
.  ||| S:712 E:714 ||| .
After  ||| S:714 E:720 ||| IN
a  ||| S:720 E:722 ||| DT
brief  ||| S:722 E:728 ||| JJ
decline  ||| S:728 E:736 ||| NN
in  ||| S:736 E:739 ||| IN
their  ||| S:739 E:745 ||| PRP$
use  ||| S:745 E:749 ||| NN
with  ||| S:749 E:754 ||| IN
the  ||| S:754 E:758 ||| DT
introduction  ||| S:758 E:771 ||| NN
of  ||| S:771 E:774 ||| IN
oral  ||| S:774 E:779 ||| JJ
atypical  ||| S:779 E:788 ||| JJ
antipsychotics ||| S:788 E:802 ||| NN
,  ||| S:802 E:804 ||| ,
LAIs  ||| S:804 E:809 ||| NNS
are  ||| S:809 E:813 ||| VBP
regaining  ||| S:813 E:823 ||| VBG
a  ||| S:823 E:825 ||| DT
central  ||| S:825 E:833 ||| JJ
position  ||| S:833 E:842 ||| NN
in  ||| S:842 E:845 ||| IN
the  ||| S:845 E:849 ||| DT
care  ||| S:849 E:854 ||| NN
of  ||| S:854 E:857 ||| IN
long-term  ||| S:857 E:867 ||| JJ
psychosis ||| S:867 E:876 ||| NN
.  ||| S:876 E:878 ||| .
This  ||| S:878 E:883 ||| DT
comprehensive  ||| S:883 E:897 ||| JJ
review  ||| S:897 E:904 ||| NN
of  ||| S:904 E:907 ||| IN
current  ||| S:907 E:915 ||| JJ
knowledge  ||| S:915 E:925 ||| NN
makes  ||| S:925 E:931 ||| VBZ
a  ||| S:931 E:933 ||| DT
timely  ||| S:933 E:940 ||| JJ
contribution ||| S:940 E:952 ||| NN
.  ||| S:952 E:954 ||| .
